Effect of nifedipine on carbohydrate metabolism and serum lipoproteins in hypertensive patients with and without diabetes mellitus.
Newly diagnosed hypertensive patients, and patients with hypertension which was not controlled by their existing therapy, were studied in a single-blind, placebo-controlled trial. Criteria for inclusion in the study were a systolic blood pressure less than 160 mmHg and a diastolic blood pressure greater than 95 mmHg. The study group was composed of 15 non-diabetic patients, 14 patients with non-insulin dependent diabetes mellitus (NIDDM) and 13 patients with insulin-dependent diabetes mellitus (IDDM). Mean supine and erect, systolic and diastolic blood pressure were reduced in all three groups after 2 and 14-16 weeks of nifedipine therapy (P less than 0.001). Mean fasting blood glucose, mean haemoglobin A1, mean total serum cholesterol, mean high density lipoprotein (HDL) cholesterol and mean serum triglycerides were not affected by nifedipine in any of the three groups over the 14-16 weeks' treatment. Forty out of the 42 patients entering, completed the study. One patient with NIDDM and angina died from a myocardial infarction in the final 4 weeks of the study, and one non-diabetic patient was unable to tolerate nifedipine after two weeks of treatment and was withdrawn from the study. No patients were withdrawn due to treatment failure.
Benaim
M E
ME
Department of Medicine, Bury General Hospital, Lancashire, U.K.
Macdonald
G
G
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D050260:Carbohydrate Metabolism; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000378:metabolism*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000378:metabolism*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000494:pharmacology*
D008074:Lipoproteins; D009543:Nifedipine